Bruce Lubotsky Levin

ORCID: 0000-0003-3817-5503
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mental Health Treatment and Access
  • Healthcare Policy and Management
  • Health Policy Implementation Science
  • Primary Care and Health Outcomes
  • Child and Adolescent Psychosocial and Emotional Development
  • Web and Library Services
  • Atrial Fibrillation Management and Outcomes
  • Community Health and Development
  • Child and Adolescent Health
  • Acute Ischemic Stroke Management
  • School Health and Nursing Education
  • Psychiatric care and mental health services
  • Heart Failure Treatment and Management
  • HIV, Drug Use, Sexual Risk
  • Health and Medical Research Impacts
  • Homelessness and Social Issues
  • Adolescent Sexual and Reproductive Health
  • Library Science and Information Literacy
  • Substance Abuse Treatment and Outcomes
  • Behavioral Health and Interventions
  • Geriatric Care and Nursing Homes
  • Cardiovascular Function and Risk Factors
  • HIV/AIDS Research and Interventions
  • Obesity, Physical Activity, Diet
  • Health Sciences Research and Education

University of South Florida
2011-2024

Behavioral Health Services
2021

Columbia University
1988-2019

Columbia University Irving Medical Center
2014-2019

New York Proton Center
2019

Florida College
2017

New York Psychoanalytic Society and Institute
2016

Birmingham City University
2015

University of Birmingham
2015

Colorado Neurological Institute
2010

Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate recurrence. Therefore, we investigated whether warfarin, which effective and superior to aspirin prevention cardiogenic embolism, would also prove recurrent stroke with prior noncardioembolic stroke.

10.1056/nejmoa011258 article EN New England Journal of Medicine 2001-11-15

Background and Purpose— Intravenous alteplase (rtPA) remains the only approved treatment for acute ischemic stroke, but its use limited. In a previous pilot dose-escalation study, intravenous tenecteplase showed promise as potentially safer alternative. Therefore, Phase IIB clinical trial was begun to (1) choose best dose of carry forward; (2) provide evidence either or futility further testing versus rtPA. If established, then would continue III efficacy comparing selected standard Methods—...

10.1161/strokeaha.109.572040 article EN Stroke 2010-02-26

IN RECENT YEARS, CONSIDERABLE EFforts have been devoted to developing treatments aimed at restoring cerebral perfusion or limiting neuronal damage following acute ischemic stroke.Recognition of the "ischemic penumbra," a region reduced blood flow in which cell death might be prevented, 1 has focused attention on that minimize reverse brain when administered soon after stroke onset.Enlargement infarct volume is determined by changes metabolism caused initiation cascade.This cascade involves...

10.1001/jama.285.13.1719 article EN JAMA 2001-04-04

Thymidine kinase 2, encoded by the nuclear gene TK2, is required for mitochondrial DNA maintenance. Autosomal recessive TK2 mutations cause depletion and multiple deletions of mtDNA that manifest predominantly as a myopathy usually beginning in childhood progressing relentlessly. We investigated safety efficacy deoxynucleoside monophosphate therapies.We administered monophosphates to 16 TK2-deficient patients under compassionate use program.In 5 with early onset severe disease, survival...

10.1002/ana.25506 article EN Annals of Neurology 2019-05-24

Background Thymine kinase 2 (TK2) is a mitochondrial matrix protein encoded in nuclear DNA and phosphorylates the pyrimidine nucleosides: thymidine deoxycytidine. Autosomal recessive TK2 mutations cause spectrum of disease from infantile onset to adult manifesting primarily as myopathy. Objective To perform retrospective natural history study large cohort patients with deficiency. Methods The was conducted by 42 investigators across 31 academic medical centres. Results We identified 92...

10.1136/jmedgenet-2017-105012 article EN cc-by Journal of Medical Genetics 2018-03-30

<i>Background and Purpose:</i> We performed a combination of prespecified exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) cohort. <i>Methods:</i> The WARSS compared efficacy adjusted-dose warfarin (INR 1.4–2.8) aspirin (325 mg/day) for recurrent ischemic stroke or death within 2 years. effect was with respect sociodemographic vascular risk factors, subtype,...

10.1159/000092331 article EN Cerebrovascular Diseases 2006-01-01

Background Clinical trials undertaken by industrialized nations in undeveloped pose several critical ethical dilemmas. One key potential problem concerns misunderstandings of the consent process participants. Though other reports have begun to explore this area, needs remain identify specific areas misunderstanding. Purpose To deficits comprehension during processes Mali, West Africa. Methods After obtaining informed for participation a malaria vaccine trial being conducted two African...

10.1191/1740774506cn150oa article EN Clinical Trials 2006-06-01

Background and Purpose— In heart failure (HF), left ventricular ejection fraction (LVEF) is inversely associated with mortality cardiovascular outcomes. Its relationship stroke controversial, as the effect of antithrombotic treatment. We studied LVEF events in patients HF different treatments. Methods— Warfarin Versus Aspirin Reduced Ejection Fraction (WARCEF) trial, 2305 systolic (LVEF≤35%) sinus rhythm were randomized to warfarin or aspirin followed for 3.5±1.8 years. Although no...

10.1161/strokeaha.116.013679 article EN Stroke 2016-06-29

In this volume, authorities from around the United States and a variety of perspectives analyze discuss key topics in women's mental health, including empowerment, substance abuse, severe illness interpersonal violence. Issues examined first part focus on service delivery - for example, organizational structure delivery, gender racial disparities, challenges women face as health administrators. Contributors to Part Two explore special issues populations, who have survived trauma such sexual...

10.5860/choice.36-1045 article EN Choice Reviews Online 1998-10-01

This 1982 national survey of all operational health maintenance organizations (HMOs) provides information on the current status mental services, benefits, costs, and utilization within HMOs, updating augmenting a 1978 study. Approximately 94 per cent responding HMOs offered service coverage; over one-half (54 cent) alcohol drug abuse coverage. The present coverage benefits services continue to reflect greater variability vis-a-vis other HMOs. Over (57 provided for 30 days inpatient (per...

10.2105/ajph.74.5.453 article EN American Journal of Public Health 1984-05-01

This 1978 national survey of all operating Health Maintenance Organizations (HMOs) provided information on the current status mental health services utilization and service coverage within HMOs. It achieved a 68 per cent response rate. Approximately 90 (108) HMOs offered through basic or supplemental plans; HMO organization characteristics reflected relative heterogeneity; mean monthly costs for plan (physical services) were $33.85 (for individuals) $95.15 families); reported lower physical...

10.2105/ajph.69.11.1120 article EN American Journal of Public Health 1979-11-01

The aim of this study is to examine the relationship between time in therapeutic range (TTR) and clinical outcomes heart failure patients sinus rhythm treated with warfarin.We used data from Warfarin versus Aspirin Reduced Cardiac Ejection Fraction (WARCEF) trial assess TTR WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), death alone, ischemic stroke major hemorrhage net benefit (primary combined). Multivariable Cox models were how event risk changed compare high...

10.1161/circheartfailure.114.001725 article EN Circulation Heart Failure 2015-04-08

Timely linkage to care by newly-diagnosed HIV+ individuals remains a significant challenge achieving UNAIDS 90-90-90 goals. Current World Health Organization (WHO) guidelines recommend initiating anti-retroviral treatment (ART) regardless of CD4+ count, with priority given those <350 cells/μl. We evaluated the impact not having day-of-diagnosis count blood draw, as recommended South African guidelines, on time linkage, using data from prospective cohort study.Individuals (N = 2773) were...

10.1371/journal.pone.0162085 article EN cc-by PLoS ONE 2016-10-05
Coming Soon ...